SI2533640T1 - Postopki sinteze derivatov dihidropiridoftalazinona - Google Patents
Postopki sinteze derivatov dihidropiridoftalazinonaInfo
- Publication number
- SI2533640T1 SI2533640T1 SI201131061T SI201131061T SI2533640T1 SI 2533640 T1 SI2533640 T1 SI 2533640T1 SI 201131061 T SI201131061 T SI 201131061T SI 201131061 T SI201131061 T SI 201131061T SI 2533640 T1 SI2533640 T1 SI 2533640T1
- Authority
- SI
- Slovenia
- Prior art keywords
- processes
- synthesizing
- dihydropyridophthalazinone derivatives
- derivatives
- synthesizing dihydropyridophthalazinone
- Prior art date
Links
- 230000002194 synthesizing effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/06—Peri-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30245710P | 2010-02-08 | 2010-02-08 | |
| PCT/US2011/023965 WO2011097602A1 (en) | 2010-02-08 | 2011-02-08 | Processes of synthesizing dihydropyridophthalazinone derivatives |
| EP11740513.4A EP2533640B1 (en) | 2010-02-08 | 2011-02-08 | Processes of synthesizing dihydropyridophthalazinone derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI2533640T1 true SI2533640T1 (sl) | 2017-02-28 |
Family
ID=44354222
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201131061T SI2533640T1 (sl) | 2010-02-08 | 2011-02-08 | Postopki sinteze derivatov dihidropiridoftalazinona |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US8765945B2 (enExample) |
| EP (1) | EP2533640B1 (enExample) |
| JP (1) | JP5735988B2 (enExample) |
| KR (1) | KR101826652B1 (enExample) |
| CN (1) | CN102834008B (enExample) |
| AU (1) | AU2011213584B2 (enExample) |
| BR (1) | BR112012019648B1 (enExample) |
| CA (1) | CA2788114C (enExample) |
| CY (1) | CY1118575T1 (enExample) |
| DK (1) | DK2533640T3 (enExample) |
| ES (1) | ES2606174T3 (enExample) |
| HU (1) | HUE030794T2 (enExample) |
| IL (1) | IL221170A (enExample) |
| MX (1) | MX340319B (enExample) |
| PL (1) | PL2533640T3 (enExample) |
| PT (1) | PT2533640T (enExample) |
| RU (1) | RU2561732C2 (enExample) |
| SG (1) | SG182784A1 (enExample) |
| SI (1) | SI2533640T1 (enExample) |
| WO (1) | WO2011097602A1 (enExample) |
| ZA (1) | ZA201205538B (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2326650B9 (en) | 2008-08-06 | 2014-09-10 | BioMarin Pharmaceutical Inc. | Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp) |
| CA2787844C (en) | 2010-02-03 | 2019-08-27 | Biomarin Pharmaceutical Inc. | Dihydropyridophthalazinone inhibitors of poly(adp-ribose) polymerase (parp) for use in treatment of diseases associated with a pten deficiency |
| PL2533640T3 (pl) | 2010-02-08 | 2017-06-30 | Medivation Technologies, Inc. | Sposób syntezy pochodnych dihydropirydoftalazynonu |
| EP2630146B1 (en) | 2010-10-21 | 2020-07-01 | Medivation Technologies LLC | Crystaline (8s,9r)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1h-1,2,4-triazol-5-yl)-8,9-dihydro-2h-pyrido[4,3,2-de]phtalazin-3(7h)-one tosylate salt |
| EP3038600B1 (en) | 2013-08-27 | 2020-06-03 | Northeastern University | Nanoparticle drug delivery system and method of treating cancer and neurotrauma |
| CN105916846A (zh) * | 2013-11-07 | 2016-08-31 | 麦迪韦逊科技有限公司 | 用于合成经保护的n-烷基三唑甲醛的三唑中间体 |
| JP2017523243A (ja) * | 2014-07-31 | 2017-08-17 | メディヴェイション テクノロジーズ， インコーポレーテッド | （２ｓ，３ｓ）−メチル ７−フルオロ−２−（４−フルオロフェニル）−３−（１−メチル−１ｈ−１，２，４−トリアゾール−５−イル）−４−オキソ−１，２，３，４−テトラヒドロキノリン−５−カルボキシレートの共形成剤塩、およびそれらを製造する方法 |
| CN104557917A (zh) * | 2014-12-12 | 2015-04-29 | 重庆博腾制药科技股份有限公司 | 一种5-卤代氮杂环吲哚的制备方法 |
| JP6786761B2 (ja) * | 2015-05-26 | 2020-11-18 | ディーエスエム アイピー アセッツ ビー．ブイ．Ｄｓｍ Ｉｐ Ａｓｓｅｔｓ Ｂ．Ｖ． | Ｓｆｃによるキラル異性体の分離 |
| US9708319B1 (en) * | 2016-06-13 | 2017-07-18 | Yong Xu | Synthesis of PARP inhibitor talazoparib |
| WO2018122168A1 (en) | 2016-12-29 | 2018-07-05 | Bayer Pharma Aktiengesellschaft | Combinations of bub1 kinase and parp inhibitors |
| BR112020006371A2 (pt) | 2017-10-13 | 2020-09-29 | Merck Patent Gmbh | combinação de um inibidor de parp e um antagonista de ligação de eixo de pd-1 |
| TW201938165A (zh) | 2017-12-18 | 2019-10-01 | 美商輝瑞股份有限公司 | 治療癌症的方法及組合療法 |
| US20210355223A1 (en) | 2018-11-05 | 2021-11-18 | Pfizer Inc. | Combinations for Treating Cancer |
| WO2021181233A2 (en) | 2020-03-09 | 2021-09-16 | Pfizer Inc. | Fusion proteins and uses thereof |
| CA3201467A1 (en) | 2020-11-13 | 2022-05-19 | Pfizer Inc. | Talazoparib soft gelatin capsule dosage form |
| EP4256088A1 (en) | 2020-12-07 | 2023-10-11 | Pfizer Inc. | Methods of identifying a tumor that is sensitive to treatment with talazoparib and methods of treatment thereof |
| US20240180906A1 (en) | 2021-03-24 | 2024-06-06 | Pfizer Inc. | Combination of Talazoparib and an Anti-Androgen for the Treatment of DDR Gene Mutated Metastatic Castration-Sensitive Prostate Cancer |
| WO2023131894A1 (en) | 2022-01-08 | 2023-07-13 | Pfizer Inc. | Genomic loss of heterozygosity as a predictive biomarker for treatment with talazoparib and methods of treatment thereof |
| TWI883565B (zh) | 2022-10-02 | 2025-05-11 | 美商輝瑞大藥廠 | 用於治療轉移性去勢抵抗性前列腺癌之他拉唑帕尼及恩雜魯胺之組合 |
| TW202425976A (zh) | 2022-12-17 | 2024-07-01 | 美商輝瑞大藥廠 | 用於治療轉移性去勢抵抗性前列腺癌之他拉唑帕尼及恩雜魯胺之組合 |
| WO2025210510A1 (en) | 2024-04-04 | 2025-10-09 | Pfizer Inc. | Tmprss2-erg and rb1 as predictive biomarkers for treatment with a parp inhibitor |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4415504A (en) | 1981-09-21 | 1983-11-15 | Tanabe Seiyaku Co., Ltd. | p-Hydroxyphenylglycine.α-phenylethanesulfonate, process for production thereof and utilization thereof in resolution of p-hydroxyphenylglycine |
| JPS58225065A (ja) * | 1982-06-21 | 1983-12-27 | Nippon Shinyaku Co Ltd | ２−キノロン誘導体 |
| US5328905A (en) * | 1987-07-20 | 1994-07-12 | Duphar International Research B.V. | 8,9-anellated-1,2,3,4-tetrahydro-β-carboline derivatives |
| SK278998B6 (sk) * | 1991-02-01 | 1998-05-06 | Merck Sharp & Dohme Limited | Deriváty imidazolu, triazolu a tetrazolu, spôsob i |
| GB9505538D0 (en) | 1995-03-18 | 1995-05-03 | Ciba Geigy Ag | New compounds |
| ID19155A (id) | 1996-12-13 | 1998-06-18 | Tanabe Seiyaku Co | Turunan-turunan piridin, pembuatannya dan intermediet untuk pembuatannya |
| DE19727410A1 (de) | 1997-06-27 | 1999-01-07 | Hoechst Schering Agrevo Gmbh | 3-(5-Tetrazolylcarbonyl)-2-chinolone und diese enthaltende nutzpflanzenschützende Mittel |
| US6514983B1 (en) | 1997-09-03 | 2003-02-04 | Guilford Pharmaceuticals Inc. | Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage |
| TW430656B (en) | 1997-12-03 | 2001-04-21 | Dainippon Ink & Chemicals | Quinolinone derivative, method for preparing the same, and anti-allergic agent |
| CA2332239A1 (en) | 1998-05-15 | 1999-11-25 | Guilford Pharmaceuticals Inc. | Fused tricyclic compounds which inhibit parp activity |
| DE19921567A1 (de) * | 1999-05-11 | 2000-11-16 | Basf Ag | Verwendung von Phthalazine-Derivaten |
| JP2001302669A (ja) * | 2000-04-18 | 2001-10-31 | Meiji Seika Kaisha Ltd | 三環性フタラジノン誘導体 |
| JP2002284699A (ja) | 2001-03-28 | 2002-10-03 | Sumitomo Pharmaceut Co Ltd | 視細胞変性疾患治療剤 |
| AR036081A1 (es) | 2001-06-07 | 2004-08-11 | Smithkline Beecham Corp | Compuesto de 1,2-dihidroquinolina, su uso para preparar una composicion farmaceutica, metodos para prepararlo y compuestos del acido 2-aminobenzoico n-alquilado de utilidad como intermediarios en dichos metodos |
| SE0102315D0 (sv) | 2001-06-28 | 2001-06-28 | Astrazeneca Ab | Compounds |
| RU2292337C2 (ru) * | 2002-02-19 | 2007-01-27 | Оно Фармасьютикал Ко., Лтд. | Конденсированные производные пиридазина и лекарственные препараты, содержащие данные соединения в качестве активного ингредиента |
| EP1340819A1 (en) | 2002-02-28 | 2003-09-03 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Microsatellite markers |
| GB0221443D0 (en) | 2002-09-16 | 2002-10-23 | Glaxo Group Ltd | Pyridine derivates |
| EP1400244A1 (en) * | 2002-09-17 | 2004-03-24 | Warner-Lambert Company LLC | New spirocondensed quinazolinones and their use as phosphodiesterase inhibitors |
| EP1582520A1 (en) * | 2002-11-12 | 2005-10-05 | Mochida Pharmaceutical Co., Ltd. | Novel parp inhibitors |
| EP1633724B1 (en) * | 2003-03-12 | 2011-05-04 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
| WO2004105700A2 (en) | 2003-05-28 | 2004-12-09 | Guildford Pharmaceuticals, Inc. | Compounds, methods and pharmaceutical compositions for inhibiting parp |
| US7269138B2 (en) * | 2003-06-04 | 2007-09-11 | Motorola, Inc. | Distributed MAC protocol facilitating collaborative ranging in communications networks |
| UA85576C2 (ru) | 2004-02-18 | 2009-02-10 | Астразенека Аб | Тетразольные соединения и их применение в качестве метаботропических антагонистов рецепторов глутамата |
| GB0612971D0 (en) | 2006-06-30 | 2006-08-09 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| US8198448B2 (en) | 2006-07-14 | 2012-06-12 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
| AU2008247102B2 (en) | 2007-05-03 | 2011-11-24 | Pfizer Limited | 2 -pyridine carboxamide derivatives as sodium channel modulators |
| EP2178875A1 (en) | 2007-08-22 | 2010-04-28 | 4Sc Ag | Indolopyridines as inhibitors of the kinesin spindle protein (eg5 ) |
| SI2209375T1 (sl) * | 2007-10-03 | 2014-12-31 | Eisai Inc. | Spojine inhibitorja PARP in metode uporabe |
| JP2011511078A (ja) | 2008-02-06 | 2011-04-07 | レアド トヘラペウトイクス，インコーポレーテッド | ポリ（ａｄｐリボース）ポリメラーゼ（ｐａｒｐ）のベンズオキサゾールカルボキサミド阻害剤 |
| EP2326650B9 (en) | 2008-08-06 | 2014-09-10 | BioMarin Pharmaceutical Inc. | Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp) |
| CA2735560A1 (en) | 2008-08-12 | 2010-02-18 | Boehringer Ingelheim International Gmbh | Process for preparing cycloalkyl-substituted piperazine compounds |
| CA2787844C (en) | 2010-02-03 | 2019-08-27 | Biomarin Pharmaceutical Inc. | Dihydropyridophthalazinone inhibitors of poly(adp-ribose) polymerase (parp) for use in treatment of diseases associated with a pten deficiency |
| US20110190266A1 (en) * | 2010-02-04 | 2011-08-04 | Daniel Chu | 5,6,6a,7,8,9-HEXAHYDRO-2H-PYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) |
| PL2533640T3 (pl) | 2010-02-08 | 2017-06-30 | Medivation Technologies, Inc. | Sposób syntezy pochodnych dihydropirydoftalazynonu |
| WO2011130661A1 (en) | 2010-04-16 | 2011-10-20 | Biomarin Pharmaceutical Inc. | Methods of using dihydropyridophthalazinone inhibitors of poly (adp-ribose)polymerase (parp) |
| WO2011140009A1 (en) | 2010-05-04 | 2011-11-10 | Biomarin Pharmaceutical Inc. | Methods of using semi-synthetic glycopeptides as antibacterial agents |
| EP2630146B1 (en) * | 2010-10-21 | 2020-07-01 | Medivation Technologies LLC | Crystaline (8s,9r)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1h-1,2,4-triazol-5-yl)-8,9-dihydro-2h-pyrido[4,3,2-de]phtalazin-3(7h)-one tosylate salt |
| WO2012166151A1 (en) | 2011-06-03 | 2012-12-06 | Biomarin Pharmaceutical Inc. | Use of dihydropyridophthalazinone inhibitors of poly (adp-ribose) polymerase (parp) in the treatment of myelodysplastic syndrome (mds) and acute myeloid leukaemia (aml) |
| WO2013028495A1 (en) | 2011-08-19 | 2013-02-28 | Biomarin Pharmaceutical Inc. | Dihydropyridophthalazinone inhibitors of poly (adp-ribose) polymerase (parp) for the treatment of multiple myeloma |
| US20130053365A1 (en) * | 2011-08-30 | 2013-02-28 | Biomarin Pharmaceutical, Inc. | Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp) |
| CN105916846A (zh) | 2013-11-07 | 2016-08-31 | 麦迪韦逊科技有限公司 | 用于合成经保护的n-烷基三唑甲醛的三唑中间体 |
| JP2017523243A (ja) | 2014-07-31 | 2017-08-17 | メディヴェイション テクノロジーズ， インコーポレーテッド | （２ｓ，３ｓ）−メチル ７−フルオロ−２−（４−フルオロフェニル）−３−（１−メチル−１ｈ−１，２，４−トリアゾール−５−イル）−４−オキソ−１，２，３，４−テトラヒドロキノリン−５−カルボキシレートの共形成剤塩、およびそれらを製造する方法 |
-
2011
- 2011-02-08 PL PL11740513T patent/PL2533640T3/pl unknown
- 2011-02-08 AU AU2011213584A patent/AU2011213584B2/en not_active Ceased
- 2011-02-08 RU RU2012138345/04A patent/RU2561732C2/ru active
- 2011-02-08 HU HUE11740513A patent/HUE030794T2/en unknown
- 2011-02-08 CA CA2788114A patent/CA2788114C/en active Active
- 2011-02-08 US US13/023,140 patent/US8765945B2/en active Active
- 2011-02-08 PT PT117405134T patent/PT2533640T/pt unknown
- 2011-02-08 SI SI201131061T patent/SI2533640T1/sl unknown
- 2011-02-08 EP EP11740513.4A patent/EP2533640B1/en active Active
- 2011-02-08 JP JP2012552143A patent/JP5735988B2/ja active Active
- 2011-02-08 CN CN201180017690.6A patent/CN102834008B/zh active Active
- 2011-02-08 BR BR112012019648-0A patent/BR112012019648B1/pt not_active IP Right Cessation
- 2011-02-08 MX MX2012008903A patent/MX340319B/es active IP Right Grant
- 2011-02-08 ES ES11740513.4T patent/ES2606174T3/es active Active
- 2011-02-08 WO PCT/US2011/023965 patent/WO2011097602A1/en not_active Ceased
- 2011-02-08 DK DK11740513.4T patent/DK2533640T3/en active
- 2011-02-08 SG SG2012056123A patent/SG182784A1/en unknown
- 2011-02-08 KR KR1020127021601A patent/KR101826652B1/ko not_active Expired - Fee Related
-
2012
- 2012-07-23 ZA ZA2012/05538A patent/ZA201205538B/en unknown
- 2012-07-29 IL IL221170A patent/IL221170A/en active IP Right Grant
-
2014
- 2014-06-02 US US14/293,642 patent/US9926303B2/en active Active
-
2016
- 2016-12-28 CY CY20161101354T patent/CY1118575T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL221170A0 (en) | Processes of synthesizing dihydropyridophthalazinone derivatives | |
| IL268953B (en) | A process to form cycloalkylcarboxamido indole compounds | |
| IL237581B (en) | Derivatives of 6-oxo-pyrazinopyrrolopyrimidines | |
| PT3329775T (pt) | Processos para a síntese de compostos de diariltiohidantoína e diarilhidantoína | |
| ZA201308086B (en) | Derivatives of 1-anino-2-cyclopropylboronic acid | |
| PL2609120T3 (pl) | Ulepszony sposób wytwarzania sugammadeksu | |
| PL2542531T3 (pl) | Sposób syntezy fipronilu | |
| IL221132A0 (en) | Derivatives of betulin | |
| IL222900A (en) | Forms of Rifaximin | |
| GB201004096D0 (en) | Production of polyhydroalkanoates | |
| IL222474A0 (en) | Method of synthesis | |
| EP2596007A4 (en) | PROCESS FOR THE PREPARATION OF 17-DEOXY-CORTICOSTEROIDS | |
| IL223926A0 (en) | Synthesis of cyclopentaquinazolines | |
| IL226041A0 (en) | Polymorphic forms of pebuxostat | |
| ZA201300546B (en) | Process for the preparation of 3-haloalkylpyrazoles | |
| PT2603319E (pt) | Processo para a preparação de uretanos | |
| EP2619191A4 (en) | NEW POLYMORPHS OF FEBUXOSTAT | |
| PL2399911T3 (pl) | Polimorfy febuksostatu | |
| PT2390246T (pt) | Processo para a preparação de aminaftona | |
| EP2537851A4 (en) | PROCESS FOR PREPARING B-GLYCOSIDE COMPOUNDS | |
| PL2598504T3 (pl) | Sposób otrzymywania dimiracetamu | |
| ZA201208995B (en) | Method of synthesis | |
| IL243320A0 (en) | Intermediates of teroarylpiperidine and piperazine derivatives | |
| IL224304A (en) | A process for making dichlorobulben |